CD274 and cervical carcinoma: Since Pembrolizumab was first clinically approved by the FDA in September 2014 (15), only six clinical trials concerning PD-1/PD-L1 inhibitors have published preliminary results for cervical cancer until 2020 (16–21), most being single-arm clinical trials on a small scale.